LEAAPS/CP-2021-05: LeAAPS Trial Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Purpose

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

Inclusion Criteria

AGES ELIGIBLE FOR STUDY

18 Years and older (Adult,  Older Adult )

SEXES ELIGIBLE FOR STUDY

All

ACCEPTS HEALTHY VOLUNTEERS

Yes

Inclusion Criteria:

  • Subjects ≥ 18 years of age
  • Documentation of any of the following clinical criteria:

    • CHA2DS2-VASc ≥ 4 with age ≥ 65
    • CHA2DS2-VASc ≥ 4 with significant left atrium enlargement or elevated NT-proBNP
    • CHA2DS2-VASc = 3 with age ≥ 75
    • CHA2DS2-VASc = 3 with significant left atrium enlargement or elevated NT-proBNP
    • CHA2DS2-VASc score = 2 with age ≥ 65 and significant left atrium enlargement or elevated NT-proBNP

Exclusion Criteria

  • Documentation of any of the following clinical criteria:

    • CHA2DS2-VASc ≥ 4 with age ≥ 65
    • CHA2DS2-VASc ≥ 4 with significant left atrium enlargement or elevated NT-proBNP
    • CHA2DS2-VASc = 3 with age ≥ 75
    • CHA2DS2-VASc = 3 with significant left atrium enlargement or elevated NT-proBNP
    • CHA2DS2-VASc score = 2 with age ≥ 65 and significant left atrium enlargement or elevated NT-proBNP

Exclusion Criteria:

  • Clinically significant atrial fibrillation or atrial flutter:

    • Anytime in the past and
    • Documented by an electrocardiographic recording and
    • Episode lasting 6 minutes or longer1*
  • Prior procedure involving opening the pericardium or entering the pericardial space
  • Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
  • Planned cardiac surgical procedure using non-sternotomy approaches

    o Partial sternotomies will be allowed.

  • Patients whose planned procedure is a heart transplant or implantation of any ventricular assist devices
  • Active endocarditis
  • Active systemic infection at the time of cardiac surgery requiring antibiotics, including known SARS-CoV2 infections regardless of symptoms
  • Known allergy to Nitinol or nickel sensitivity
  • Known medical condition with expected survival of less than 1 year
  • Other comorbidities that in the investigator's opinion make the subject unsuitable candidate to complete the protocol required visits.
  • Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial.
  • Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
  • Pregnancy
  • Known severe symptomatic carotid disease
Stephan Bailey, MD
Thoracic and Cardiac Surgery
Allegheny General Hospital
Contact

For more information about this trial, please send an email to ClinicalTrials@ahn.org.

Are you a patient interested in participating in a clinical trial?

Connect with one of our specialists. We provide comprehensive, patient-centered care for a broad spectrum of conditions and treatments.